TY - JOUR
T1 - Knowledge gaps in cardiovascular care of the older adult population
T2 - A scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society
AU - American College of Cardiology; and American Geriatrics Society
AU - American Heart Association Older Populations Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council
AU - Rich, Michael W.
AU - Chyun, Deborah A.
AU - Skolnick, Adam H.
AU - Alexander, Karen P.
AU - Forman, Daniel E.
AU - Kitzman, Dalane W.
AU - Maurer, Mathew S.
AU - McClurken, James B.
AU - Resnick, Barbara M.
AU - Shen, Win K.
AU - Tirschwell, David L.
N1 - Funding Information:
Writing Group Disclosures Writing Group Member Employment Research Grant Other Research Support Speakers Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Michael W. Rich Washington University School of Medicine NIA ∗ ; NHLBI ∗ None None None None None None Deborah A. Chyun New York University None None None None None Qatar National Research Fund ∗ None Karen P. Alexander Duke University Medical Center None None None None None None None Daniel E. Forman University of Pittsburgh Medical Center None None None None None None None Dalane W. Kitzman Wake Forest University School of Medicine NIH † ; Novartis † None None None Gilead, Inc. Stock Ownership † ; Relypsa Inc. ∗ GSK ∗ ; Relypsa ∗ ; Regeneron ∗ ; AbbVie † ; DC Devices ∗ ; Abbott Pharmaceuticals ∗ ; Actavis ∗ ; ICON † None Mathew S. Maurer Columbia College of Physicians and Surgeons None None None None None None None James B. McClurken Doylestown Health Heart Institute Silver AMI ∗ None None None None None None Barbara M. Resnick University of Maryland None None None None None None None Win K. Shen Mayo Clinic None None None None None None None Adam H. Skolnick NYU School of Medicine None None None None None None None David L. Tirschwell Harborview Medical Center St. Jude Medical † ; Bayer ∗ None None None None None None
Funding Information:
Reviewer Disclosures Reviewer Employment Research Grant Other Research Support Speakers Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Jeffrey L. Anderson Intermountain Healthcare None None None None None None None Susan Bell Vanderbilt University NIH/NICHD (2K12HD043483-11) † Eisenstein Women’s Heart Fund ∗ None None None None None James Blankenship Geisinger Medical Center None Tryton Medical ∗ ; Abiomed ∗ ; AstraZeneca ∗ ; Boston Scientific ∗ ; Regado Biosciences ∗ ; Volcano ∗ ; Abbott Vascular ∗ (Principal Investigator at Geisinger Medical Center for multicenter industry-funded research trials sponsored by these companies) None None None None None Joseph P. Drozda Mercy Health None None None None None None My nondependent son is a sales representative for Boston Scientific Corporation † Andrew E. Epstein University of Pennsylvania Biotronik † ; Boston Scientific † ; Medtronic; Sorin Medical † ; St. Jude Medical † None None Yes (1 current case) ∗ None Boston Scientific † ; Medtronic † ; St. Jude Medical † ; Population Health Research Institute ∗ None Lee A. Fleisher University of Pennsylvania None None None None None Member, Medical Advisory Board to Technical Expert Panel of Blue Cross/Blue Shield Association ∗ None Rebecca Gary Emory University None None None None None None None Sarah Goodlin Portland VAMC Medtronic ∗ None None None None None None Lawrence Izzo State University of New York at Buffalo; Erie County Medical Center None None None None None None None Mariell Jessup University of Pennsylvania Heart and Vascular Center None None None None None None None Glenn N. Levine Baylor College of Medicine; Michael E. DeBakey Medical Center None None None None None None None Patrick O’Gara Brigham and Women’s Hospital, Boston, MA NHLBI, Cardiothoracic Surgery Network † None None None None None None Catherine M. Otto University of Washington School of Medicine None None None None None None None Lawrence Rudski Jewish General Hospital, Montreal, Quebec None None None None None None None Nanette Wenger Emory University School of Medicine Gilead Sciences † ; NHLBI † ; Pfizer ∗ None None None None Amgen ∗ ; AstraZeneca ∗ ; Gilead Sciences † None
Publisher Copyright:
© 2016 American College of Cardiology Foundation.
PY - 2016/5/24
Y1 - 2016/5/24
N2 - The incidence and prevalence of most cardiovascular disorders increase with age, and cardiovascular disease is the leading cause of death and major disability in adults ≥75 years of age; however, despite the large impact of cardiovascular disease on quality of life, morbidity, and mortality in older adults, patients aged ≥75 years have been markedly underrepresented in most major cardiovascular trials, and virtually all trials have excluded older patients with complex comorbidities, significant physical or cognitive disabilities, frailty, or residence in a nursing home or assisted living facility. As a result, current guidelines are unable to provide evidence-based recommendations for diagnosis and treatment of older patients typical of those encountered in routine clinical practice. The objectives of this scientific statement are to summarize current guideline recommendations as they apply to older adults, identify critical gaps in knowledge that preclude informed evidence-based decision making, and recommend future research to close existing knowledge gaps. To achieve these objectives, we conducted a detailed review of current American College of Cardiology/American Heart Association and American Stroke Association guidelines to identify content and recommendations that explicitly targeted older patients. We found that there is a pervasive lack of evidence to guide clinical decision making in older patients with cardiovascular disease, as well as a paucity of data on the impact of diagnostic and therapeutic interventions on key outcomes that are particularly important to older patients, such as quality of life, physical function, and maintenance of independence. Accordingly, there is a critical need for a multitude of large population-based studies and clinical trials that include a broad spectrum of older patients representative of those seen in clinical practice and that incorporate relevant outcomes important to older patients in the study design. The results of these studies will provide the foundation for future evidence-based guidelines applicable to older patients, thereby enhancing patient-centered evidence-based care of older people with cardiovascular disease in the United States and around the world.
AB - The incidence and prevalence of most cardiovascular disorders increase with age, and cardiovascular disease is the leading cause of death and major disability in adults ≥75 years of age; however, despite the large impact of cardiovascular disease on quality of life, morbidity, and mortality in older adults, patients aged ≥75 years have been markedly underrepresented in most major cardiovascular trials, and virtually all trials have excluded older patients with complex comorbidities, significant physical or cognitive disabilities, frailty, or residence in a nursing home or assisted living facility. As a result, current guidelines are unable to provide evidence-based recommendations for diagnosis and treatment of older patients typical of those encountered in routine clinical practice. The objectives of this scientific statement are to summarize current guideline recommendations as they apply to older adults, identify critical gaps in knowledge that preclude informed evidence-based decision making, and recommend future research to close existing knowledge gaps. To achieve these objectives, we conducted a detailed review of current American College of Cardiology/American Heart Association and American Stroke Association guidelines to identify content and recommendations that explicitly targeted older patients. We found that there is a pervasive lack of evidence to guide clinical decision making in older patients with cardiovascular disease, as well as a paucity of data on the impact of diagnostic and therapeutic interventions on key outcomes that are particularly important to older patients, such as quality of life, physical function, and maintenance of independence. Accordingly, there is a critical need for a multitude of large population-based studies and clinical trials that include a broad spectrum of older patients representative of those seen in clinical practice and that incorporate relevant outcomes important to older patients in the study design. The results of these studies will provide the foundation for future evidence-based guidelines applicable to older patients, thereby enhancing patient-centered evidence-based care of older people with cardiovascular disease in the United States and around the world.
KW - ACC Scientific Statements
KW - elderly
KW - heart failure
KW - heart rhythm disorders
KW - non-cardiac surgery
KW - stroke
KW - valvular heart disease
UR - http://www.scopus.com/inward/record.url?scp=84964355762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964355762&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2016.03.004
DO - 10.1016/j.jacc.2016.03.004
M3 - Article
C2 - 27079335
AN - SCOPUS:84964355762
SN - 0735-1097
VL - 67
SP - 2419
EP - 2440
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 20
ER -